Tumor infiltrating lymphocytes in melanoma comprise high numbers of T-cell clonotypes that are lost during in vitro culture

Clinical Immunology

Volumn 96, Issue 2, 2000, Pages 94-99

  Thor Straten, Per ^a   Kirkin, Alexei F ^a   Siim, Elsebeth ^b   Dahlström, Karin ^b   Drzewiecki, Krzysztof T ^c   Seremet, Tina ^a   Zeuthen, Jesper ^a   Becker, Jürgen C ^d   Guldberg, Per ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c Rigshospitalet   (Denmark)

^d Department of Dermatology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER IMMUNOLOGY; CYTOTOXICITY TEST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0033866620     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.2000.4890     Document Type: Article

References (37)

1. Cancer vaccines
2. Tumour progression and the nature of cancer
3. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
4. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
5. Cancer vaccines based on the identification of genes encoding cancer regression antigens
6. Human tumor antigens recognized by T lymphocytes
7. Tumor-specific immune response: Current in vitro analyses may not reflect the in vivo immune status
8. Oligoclonality of tumor-infiltrating lymphocytes from human melanomas
9. Usage of T-cell receptor V beta chain genes in fresh and cultured tumor-infiltrating lymphocytes from human melanoma
10. TCR analysis reveals significant repertoire selection during in vitro lymphocyte culture
11. Detection and characterization of alpha/ beta-T-cell clonality by denaturing gradient gel electrophoresis (DGGE)
12. Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines
13. T-cell receptor variable region genes in cutaneous T-cell lymphomas
14. Situ T-cell responses against melanoma comprise high numbers of locally expanded T-cell clonotypes
15. Genes coding for melanoma antigens recognised by cytolytic T lymphocytes
16. Diversity of the cytotoxic melanoma-specific immune response: Some CTL clones recognize autologous fresh tumor cells and not tumor cell lines
17. The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response
18. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood
19. Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35)
20. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35)
21. Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells
22. Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells
23. Alterations in T cell receptor and signal transduction molecules in melanoma patients
24. Signaling defects in T lymphocytes of patients with malignancy
25. Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions
26. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy
27. Escape from hostantitumor immunity
28. Correlation between disease activity and T-cell CD3 zeta chain expression in a B-cell lymphoma
29. The V-region disease hypothesis: New evidence suggests it is probably wrong
30. Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma
31. In situ demonstration of renal-cell-carcinoma-specific T-cell clones
32. High frequency of T cell clonal expansions in primary human melanoma. Involvement of a dominant clonotype in autologous tumor recognition
33. A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion
34. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation
35. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles
36. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression
37. Expansion of major histocompatibility complex-restricted antimelanoma cytotoxic T-cell lymphocyte clones with identical T-cell receptor from tumor-infiltrating lymphocytes